Strong Q3; guidance upgrade driven by FX
08/11/19 -"Darzalex continued to gain market share in Q3, while Arzerra was once again a disappointment. Given the favourable development in FX, the revenue guidance was upgraded by DKK300m and, as operating ..."
Pages
58
Language
English
Published on
08/11/19
You may also be interested by these reports :
29/05/20
A few months after our endorsement in March 2019, Genmab (Reduce, Denmark) made a big splash on Nasdaq with one of the biggest IPOs in biotech ...
28/05/20
... or ~€-300bn, this is the latest estimate of the potential negative impact on GDP of the pandemic by the German Economic Institute. The crucial ...
08/05/20
Given that the subcutaneous formulation of the lynchpin drug, Darzalex, is now approved by the US FDA, we have increased our estimates for the drug. ...
30/04/20
We have increased our FY20 earnings on the back of a better than expected favourable product mix (higher sales contribution from the Dupixent and ...